New BP Goals Could Prevent 3 Million CVD Events Over 10 Years
Maintaining ACC/AHA goals would result in fewer events than current BP levels, prior guideline goals
MONDAY, Dec. 3, 2018 (HealthDay News) -- Achieving and maintaining 2017 American College of Cardiology/American Heart Association (ACC/AHA) blood pressure (BP) goals could prevent a greater number of cardiovascular disease (CVD) events than achieving prior U.S. guideline goals, according to a study published online Nov. 19 in Circulation.
Adam P. Bress, Pharm.D., from the University of Utah in Salt Lake City, and colleagues used data from the 2011 to 2014 National Health and Nutrition Examination Survey to estimate the number of CVD events prevented and treatment-related serious adverse events incurred over 10 years among U.S. adults with hypertension achieving 2017 ACC/AHA guideline-recommended BP goals versus current BP levels, 2003 Seventh Joint National Committee Report BP goals, and 2014 Eighth Joint National Committee panel member report BP goals.
The researchers found that over 10 years, achieving and maintaining 2017 ACC/AHA guideline goals compared with current BP levels would prevent three million CVD events; achieving and maintaining 2017 ACC/AHA guideline goals would also prevent 0.5 million CVD events compared with achieving 2003 Seventh Joint National Committee Report goals and 1.4 million compared with achieving 2014 Eighth Joint National Committee goals. Further, achieving and maintaining 2017 goals could prevent 71.9 CVD events per 1,000 treated compared with current BP levels. However, achieving 2017 guideline BP goals could also lead to nearly 3.3 million more serious adverse events over 10 years compared with current BP levels.
"Achieving and maintaining 2017 ACC/AHA BP goals could prevent a greater number of CVD events than achieving 2003 Seventh Joint National Committee Report or 2014 Eighth Joint National Committee BP goals but could also lead to more serious adverse events," the authors write.
Several authors disclosed financial ties to the pharmaceutical industry.